Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ514,5515,50,39
KB791,57920,13
PKN94,994,940,85
Msft149,93150,160,45
Nokia3,07753,0810,28
IBM134,04134,530,52
Daimler AG51,4951,50,92
PFE37,6937,930,11
22.11.2019 11:36:56
Indexy online
AD Index online
select
AD Index online
 

  • 21.11.2019
Eli Lilly (LLY, NY Consolidated)
Závěr k 21.11.2019 Změna (%) Změna (USD) Objem obchodů (ks)
114,75 0,12 0,14 2 909 502
Premarket22.11.2019 10:00:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 112,85 119,87 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.11.2019
Popis společnosti
Obecné informace
Název společnostiEli Lilly And Co
TickerLLY
Kmenové akcie:Ordinary Shares
RICLLY
ISINUS5324571083
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.09.2019
Počet zaměstnanců k 31.12.2018 38 680
Akcie v oběhu k 21.10.2019 960 130 771
Počet akcionářů k 30.09.2019 24 000
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
UliceLilly Corporate Ctr
MěstoINDIANAPOLIS
PSČ46285-0001
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 172 762 000
Fax13172763492

Business Summary: Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Financial Summary: BRIEF: For the nine months ended 30 September 2019, Eli Lilly And Co revenues increased 2% to $16.21B. Net income before extraordinary items increased 55% to $3.14B. Revenues reflect Japan segment increase of 1% to $1.84B. Net income benefited from Acquired in-process research and develop decrease of 86% to $239.6M (expense), Effect from interest rate contracts increase from $94.1M (expense) to $148.1M (income).
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 22.11.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerDavid Ricks5101.06.201701.01.2012
Chief Financial Officer, Senior Vice PresidentJoshua Smiley4901.01.201801.01.2018
Executive Vice President, General CounselMichael Harrington56
Senior Vice President - Chief Information and Digital OfficerAarti Shah54
Senior Vice President, Chief Scientific OfficerDaniel Skovronsky45
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance OfficerMelissa Barnes51
Senior Vice President - Human Resources and DiversityStephen Fry5311.02.201111.02.2011
Senior Vice President and President - Lilly Diabetes and President - Lilly USAEnrique Conterno5230.01.2009
Senior Vice President and President - Lilly Bio-MedicinesPatrik Jonsson-31.08.201931.08.2019
Senior Vice President - Global QualityJohna Norton52